Lymphocytes are white blood cells that have important immune functions. The main populations of lymphocytes are B cells, T cells and natural killer (NK) cells. They are typically (although not ...

CULVER CITY, Calif., June 02, 2025--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced that the U.S. Food and Drug Administration (FDA) has granted Expanded Access ...

Hangzhou Qihan Biotech Co., Ltd. ("Qihan" or "Qihan Biotech" or "the Company"), an industry leader in applying multiplexable genome editing technology to cell therapies and organ transplantation, ...

NK (natural killer) cells are a population of lymphocytes with both innate and adaptive immune features. They produce cytotoxic molecules and can eliminate infected cells or cancer cells. Cellular ...

ImmunityBio, Inc. today announced results presented at ASCO 2025 of the first known treatment for lymphopenia with ANKTIVA and CAR-NK therapy. This data supports that reversal of lymphopenia, a ...

Even brief exposure to tobacco smoke can trigger inflammation, weaken immunity, and raise cancer risk in organs far beyond ...

NKT cells are a subset of regulatory lymphocytes characterized by coexpression of the NK cell receptor-CD161 and an invariant T-cell receptor-α chain (V-α 14J α28).

Anktiva is designed to address BCG-unresponsive bladder cancer through its mechanism as an interleukin-15 superagonist.

CD3+CD56+ is a simple marker phenotype that groups together all NK T cells. In a 2021 paper from Lenart et al 1, the prevalence of iNKT cells when defined only by CD3+/CD56+ is between 8-13% of CD3+ T ...

The systemic lupus erythematosus (SLE) treatment pipeline is experiencing unprecedented expansion, driven by increasing disease awareness, rising pre ...

ASCO 2025 overall survival data bolster IMNN-001’s potential in advanced ovarian cancer, supported by robust translational results at ESMO Results from OVATION 2 Study reinforce IMNN-001 mechanism of ...

Consistent OS Efficacy Benefit Across Multiple Treatment Subgroups Demonstrates IMNN-001’s Ability to Recruit a Powerful Anti-Cancer Immune Response  Results, presented simultaneously in oral ...